Communications

Community updates,
October 2024

Community Update

read more

Community updates,
September 2024

Community Update

read more

Community updates,
February 2024

Community Update

read more

Community updates,
June 2023

Community Update

read more

Community updates,
November 2022

Community Update

read more

Community updates,
May 2022

Community Update

read more

Community updates,
February 2022

Community Update

read more

Community updates,
January 2022

Community Update

read more

Community updates,
December 2021

Community Update

read more

Community updates,
November 2021

Community Update

read more

Community updates,
October 2021

Community Update

read more

Community updates,
September 16, 2021

U.S. Expanded Access Program to Continue

read more

Community updates,
September 2021

Community Update

read more

Mandos Health

A world of support for all affected by NPC1

Research. Access. Collaboration.

#NoStoneLeftUnturned  #TheRightThingToDo  #BuiltForPatients

*Adrabetadex is an investigational drug that has not been approved by FDA, and FDA has not found it to be safe and effective for use to treat NPC1 or for any other use.

Home

FAQs

Expanded Access Policy

Communications

Contact us

Terms of Use  |  Privacy Policy

© 2024 Mandos, LLC.  Designed by 10 Creative